
Please try another search
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Viktor Drvota | 57 | 2016 | Chairman of the Board |
Mats Wahlgren | - | 2021 | Scientific Advisor |
Ellen K. Donnelly | 50 | 2020 | Independent Director |
Lennart Lindbom | - | 2021 | Scientific Advisor |
Eddie Weitzberg | 69 | 2021 | Scientific Advisor |
Johan Dighed | 51 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review